ATE331519T1 - Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten - Google Patents
Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheitenInfo
- Publication number
- ATE331519T1 ATE331519T1 AT02769490T AT02769490T ATE331519T1 AT E331519 T1 ATE331519 T1 AT E331519T1 AT 02769490 T AT02769490 T AT 02769490T AT 02769490 T AT02769490 T AT 02769490T AT E331519 T1 ATE331519 T1 AT E331519T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridylpyrimidine
- derivatives
- prion
- pyridylpyrimidine derivatives
- diseases
- Prior art date
Links
- YJVKLLJCUMQBHN-UHFFFAOYSA-N 2-pyridin-2-ylpyrimidine Chemical class N1=CC=CC=C1C1=NC=CC=N1 YJVKLLJCUMQBHN-UHFFFAOYSA-N 0.000 title abstract 6
- 208000024777 Prion disease Diseases 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 1
- 102000029797 Prion Human genes 0.000 abstract 3
- 108091000054 Prion Proteins 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 abstract 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 abstract 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 230000004715 cellular signal transduction Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111858 | 2001-05-16 | ||
| US29352801P | 2001-05-29 | 2001-05-29 | |
| EP01117113 | 2001-07-13 | ||
| US30589801P | 2001-07-18 | 2001-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE331519T1 true ATE331519T1 (de) | 2006-07-15 |
Family
ID=28043245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02769490T ATE331519T1 (de) | 2001-05-16 | 2002-05-16 | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20030176443A1 (de) |
| EP (2) | EP1395261B1 (de) |
| AT (1) | ATE331519T1 (de) |
| AU (1) | AU2002342878A1 (de) |
| CA (1) | CA2446939C (de) |
| DE (1) | DE60212836T2 (de) |
| WO (1) | WO2002093164A2 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030175926A1 (en) * | 2002-03-05 | 2003-09-18 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| ES2274993T3 (es) * | 2001-06-29 | 2007-06-01 | Ab Science | Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas. |
| JP2004537542A (ja) * | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用 |
| US20040266797A1 (en) * | 2001-06-29 | 2004-12-30 | Alain Moussy | Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis |
| WO2003003006A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
| ES2266553T3 (es) * | 2001-06-29 | 2007-03-01 | Ab Science | Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias. |
| WO2003002109A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| EP1461032B1 (de) * | 2001-09-20 | 2008-07-16 | AB Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
| EP1427379B1 (de) * | 2001-09-20 | 2008-08-13 | AB Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung |
| DE60307237T2 (de) * | 2002-02-27 | 2007-10-18 | Ab Science | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten |
| AU2003249369A1 (en) | 2002-06-21 | 2004-01-06 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
| EP1547996A4 (de) * | 2002-08-30 | 2006-08-02 | Bf Res Inst Inc | Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein |
| GB0222514D0 (en) | 2002-09-27 | 2002-11-06 | Novartis Ag | Organic compounds |
| AU2003242988A1 (en) * | 2003-06-06 | 2005-01-04 | Adibhatla Kali Sathya Bhujanga Rao | Process for the preparation of the anti-cancer drug imatinib and its analogues |
| ATE454152T1 (de) * | 2003-06-13 | 2010-01-15 | Novartis Pharma Gmbh | 2-aminopyrimidin-derivate als raf-kinase-hemmer |
| GB2429018A (en) | 2004-04-23 | 2007-02-14 | Laura Manuelidis | High throughput assays for transmissible spongiform encephalopathies |
| JP2008510766A (ja) * | 2004-08-27 | 2008-04-10 | ゲーペーツェー ビオテック アーゲー | ピリミジン誘導体 |
| CN101035535A (zh) * | 2004-10-18 | 2007-09-12 | 梅特维特科学私人有限公司 | 4－( 4－甲基哌嗪－1－基甲基)－N－[4－甲基－3－(4－(吡啶－3－基 )嘧啶－2－基氨基)苯基]－苯甲酰胺用于抑制酪氨酸激酶受体c－fms的用途 |
| DE602005007458D1 (de) | 2004-11-15 | 2008-07-24 | Roche Diagnostics Gmbh | Hoch-Durchsatz Prion Tests |
| DE502006005084D1 (de) * | 2005-08-15 | 2009-11-26 | Siegfried Generics Int Ag | Filmtablette oder Granulat enthaltend ein Pyridylpyrimidin |
| TW200804349A (en) * | 2005-12-23 | 2008-01-16 | Kalypsys Inc | Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases |
| BRPI0718677A2 (pt) * | 2006-11-03 | 2013-11-26 | Irm Llc | Compostos e composições como inibidores de quinases proteicas |
| EA019524B1 (ru) * | 2007-05-04 | 2014-04-30 | Айрм Ллк | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR |
| KR101122481B1 (ko) * | 2007-05-04 | 2012-02-29 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물 |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US8293757B2 (en) | 2007-08-22 | 2012-10-23 | Irm Llc | 5-(4-(haloalkoxy)phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors |
| MX2010002005A (es) * | 2007-08-22 | 2010-03-11 | Irm Llc | Derivados de 2-heteroaril-amino-pirimidina como inhibidores de cinasa. |
| JP5611826B2 (ja) * | 2007-09-04 | 2014-10-22 | ザ スクリプス リサーチ インスティテュート | タンパク質キナーゼ阻害剤としての置換されたピリミジニル−アミン |
| CN101417995B (zh) * | 2008-11-21 | 2012-06-06 | 陈依军 | 苯氧基嘧啶衍生物及其制备方法和用途 |
| JP5959537B2 (ja) | 2011-01-28 | 2016-08-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換ピリジニル−ピリミジン及び医薬としてのその使用 |
| CN110078708B (zh) * | 2019-05-08 | 2020-12-11 | 东南大学 | Smo/Bcr-Abl双靶向抑制剂及其合成方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| WO1995009847A1 (en) * | 1993-10-01 | 1995-04-13 | Ciba-Geigy Ag | Pyrimidineamine derivatives and processes for the preparation thereof |
| BR9407799A (pt) * | 1993-10-12 | 1997-05-06 | Du Pont Merck Pharma | Composição de matéria método de tratamento e composição farmaceutica |
| TW513418B (en) * | 1996-07-31 | 2002-12-11 | Otsuka Pharma Co Ltd | Thiazole derivatives, their production and use |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU747705C (en) * | 1997-12-13 | 2004-09-23 | Bristol-Myers Squibb Company | Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors |
| DE69812177T2 (de) * | 1997-12-31 | 2004-01-15 | Cephalon Inc | 3'-epi k-252a derivate |
| DE60033028T2 (de) * | 1999-04-23 | 2007-11-15 | Takeda Pharmaceutical Co. Ltd. | 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung |
| US7169778B2 (en) * | 1999-09-15 | 2007-01-30 | Warner-Lambert Company | Pteridinones as kinase inhibitors |
-
2002
- 2002-05-16 DE DE60212836T patent/DE60212836T2/de not_active Expired - Lifetime
- 2002-05-16 US US10/204,041 patent/US20030176443A1/en not_active Abandoned
- 2002-05-16 WO PCT/EP2002/005420 patent/WO2002093164A2/en not_active Ceased
- 2002-05-16 AT AT02769490T patent/ATE331519T1/de not_active IP Right Cessation
- 2002-05-16 EP EP02769490A patent/EP1395261B1/de not_active Expired - Lifetime
- 2002-05-16 AU AU2002342878A patent/AU2002342878A1/en not_active Abandoned
- 2002-05-16 EP EP06013237A patent/EP1721609A3/de not_active Withdrawn
- 2002-05-16 CA CA002446939A patent/CA2446939C/en not_active Expired - Fee Related
-
2006
- 2006-02-08 US US11/350,410 patent/US20060217404A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002342878A1 (en) | 2002-11-25 |
| EP1721609A3 (de) | 2007-01-31 |
| EP1395261B1 (de) | 2006-06-28 |
| WO2002093164A3 (en) | 2003-09-04 |
| DE60212836D1 (de) | 2006-08-10 |
| EP1395261A2 (de) | 2004-03-10 |
| WO2002093164A2 (en) | 2002-11-21 |
| US20060217404A1 (en) | 2006-09-28 |
| EP1721609A2 (de) | 2006-11-15 |
| DE60212836T2 (de) | 2007-01-25 |
| US20030176443A1 (en) | 2003-09-18 |
| CA2446939A1 (en) | 2002-11-21 |
| CA2446939C (en) | 2005-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60212836D1 (de) | Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| ATE307810T1 (de) | Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren | |
| MXPA04012965A (es) | Inhibidores virales. | |
| TR200103336T2 (tr) | Amid türevleri. | |
| CY1107747T1 (el) | Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| NO20053645L (no) | (4R)- og (4S)-diastereoisomerer av (2S)-2-[ 2-oksy-4-propylpyrrolidinyl]butanamid og farmasoytisk preparat inneholdende disse | |
| DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
| NO20060706L (no) | Inhibitorer av serinproteaser, spesielt HCV NS3-NS4A-protease | |
| CY1110969T1 (el) | 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ | |
| NO20084496L (no) | Pyridyl- og pyrimidinylsubstituerte pyrrol-, tiofen- og furanderivater som kinaseinhibitorer | |
| NO20062101L (no) | Serinproteaseinhibitorer, spesielt hcv ns3-ns4a-protease | |
| ATE349463T1 (de) | Verbrückte bizyklische serinproteaseinhibitoren | |
| NO331068B1 (no) | Benzazepinderivater for behandling av nevrologiske forstyrrelser. | |
| ECSP045378A (es) | Derivados novedosos de diazabiciclononeno | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| EP1689713A4 (de) | Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| ES2243579T3 (es) | Derivados de pirazolopirideno. | |
| BR9909597A (pt) | Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas | |
| BRPI0406646A (pt) | Compostos de(2-carboxamido)(3-amina)tiofenos, bem como composições e usos compreendendo os mesmos | |
| DK1483251T3 (da) | C3-cyano-epothilon-derivater | |
| ATE337318T1 (de) | Spiroverbindungen und diese als wirkstoff enthaltende adhäsionsmolekülinhibitoren | |
| WO2002094796A3 (en) | Benzo[g]quinoxaline derivatives as effective compounds against infectious diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1395261 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |